Sign in
4

Changes in Ownership

CytomX Therapeutics, Inc. Filed Acc 0001140361-17-012870

Chief Financial Officer sold 21,517 shares at an average $19.81 ($426,340)

  • Chief Financial Officer acquired 21,517 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Goeltz II Robert C. · Chief Financial Officer

Table I: Non-derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2017-03-20 Exercise or conversion : show line 1 in the form +21,517 $4.47 $96,241 31,306 D
2017-03-20 Sale : show line 2 in the form −10,000 $19.60 $196,000 21,306 D
2017-03-20 Sale : show line 3 in the form −11,517 $20.00 $230,340 9,789 D
Open-market sales · 21,517 sh · avg $19.81 · $426,340

Table II: Derivative

1 line
Date Transaction Shares Owned after D/I
2017-03-20 Exercise or conversion : show line 4 in the form Stock Option (Right to Buy) −21,517 217,658 D
Loading xslF345X03/doc1.xml…